COVID-19 Severity in Multiple SclerosisMaria Pia Sormani, Giovanna Borriello, Vincenzo Brescia Morra et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 74
Impact of natural menopause on multiple sclerosis: a multicentre studyDamiano Baroncini, Mauro Zaffaroni, Pietro Annovazzi et al.|Journal of Neurology Neurosurgery & Psychiatry|2019Cited by 70
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62
Vaccinations in patients with multiple sclerosis: A Delphi consensus statementAgostino Riva, Lucia Moiola, Valeria Barcella et al.|Multiple Sclerosis Journal|2020Cited by 62
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Pietro Annovazzi et al.|Journal of Neurology|2018Cited by 54